Switch to:
More From Other Websites
Mylan Down 24% Year to Date: What's Troubling the Stock? Sep 20 2017
Mylan Plans to File Application for Revefenacin in Late 2017 Sep 19 2017
Mylan and Multiple Partnerships to Advance Biosimilar Portfolio Sep 19 2017
Could Mylan’s Biosimilar Portfolio Be a Long-Term Growth Driver? Sep 19 2017
Tax inversion deals saved U.S. companies $45 mln on average -CBO Sep 18 2017
Could Mylan See a Rise in Net Profit Margins in 2017? Sep 18 2017
Why Mylan Lowered Its Revenue Guidance for 2017 Sep 18 2017
Analysts’ Recommendations for Mylan in September 2017 Sep 18 2017
Teva: When Bold Action Just Isn't Possible Sep 18 2017
Why Allergan Could Be A $300 Stock Sep 18 2017
Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle Sep 16 2017
Own Alphabet Inc. Stock? Antitrust Is on the Horizon Sep 15 2017
ETFs with exposure to Mylan NV : September 14, 2017 Sep 14 2017
Challenge of Allergan tribal patent deal in uncharted legal territory Sep 14 2017
Biosimilar 2017 Progress Report: Stocks in Focus Sep 14 2017
Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin® 24 FE Tablets Sep 14 2017
Mylan NV :MYL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Sep 13 2017
Mylan Names Dennis Zeleny as Chief Human Relations Officer Sep 13 2017
Teva Pharmaceutical on the Street: Analysts’ Recommendations in September Sep 13 2017
Mylan says Allergan misusing tribal sovereignty in patent dispute Sep 12 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK